Investing IdeasBrowse All StocksMarkets

Have your own idea? Try our Stock Screener

Header cover image

Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedNov 21, 2024
DataAggregated Company Financials
Companies7
  • 7D-6.9%
  • 3M-10.0%
  • 1Y28.9%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 7.8%, driven by declines from every company within the industry. Over the past 12 months, the industry was up 27%. Earnings are forecast to grow by 22% annually.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 21 Nov 2024CHF 52.4bCHF 10.2bCHF 943.6m40.7x55.6x5.1x
Sat, 19 Oct 2024CHF 56.1bCHF 10.2bCHF 943.4m42.3x59.5x5.5x
Mon, 16 Sep 2024CHF 57.5bCHF 10.2bCHF 937.0m44.5x61.3x5.6x
Wed, 14 Aug 2024CHF 56.4bCHF 10.2bCHF 923.6m45.1x61.1x5.5x
Fri, 12 Jul 2024CHF 55.5bCHF 10.3bCHF 1.0b47.8x55.4x5.4x
Sun, 09 Jun 2024CHF 53.1bCHF 10.3bCHF 1.0b44x53x5.2x
Tue, 07 May 2024CHF 54.3bCHF 10.3bCHF 1.0b43.5x54.2x5.3x
Thu, 04 Apr 2024CHF 58.2bCHF 10.3bCHF 1.0b45.8x58.1x5.7x
Sat, 02 Mar 2024CHF 50.7bCHF 10.2bCHF 982.2m47x51.7x5x
Mon, 29 Jan 2024CHF 46.5bCHF 10.2bCHF 1.0b42.3x45.6x4.6x
Wed, 27 Dec 2023CHF 41.8bCHF 9.8bCHF 1.5b32.4x28x4.3x
Fri, 24 Nov 2023CHF 41.4bCHF 9.8bCHF 1.5b29.9x27.7x4.2x
Sun, 22 Oct 2023CHF 38.3bCHF 9.8bCHF 1.5b26.9x25.7x3.9x
Tue, 19 Sep 2023CHF 46.8bCHF 9.8bCHF 1.5b32.7x31.4x4.8x
Thu, 17 Aug 2023CHF 52.0bCHF 9.7bCHF 1.5b40.4x33.9x5.3x
Sat, 15 Jul 2023CHF 56.4bCHF 9.7bCHF 1.6b36.1x34.5x5.8x
Mon, 12 Jun 2023CHF 58.7bCHF 9.7bCHF 1.6b37x35.9x6.1x
Wed, 10 May 2023CHF 60.4bCHF 9.7bCHF 1.6b40x36.9x6.2x
Fri, 07 Apr 2023CHF 59.4bCHF 9.7bCHF 1.7b41.6x35.6x6.1x
Sun, 05 Mar 2023CHF 59.9bCHF 9.6bCHF 1.7b34.6x36x6.3x
Tue, 31 Jan 2023CHF 56.1bCHF 9.6bCHF 1.6b32.6x34.3x5.9x
Thu, 29 Dec 2022CHF 50.0bCHF 9.2bCHF 1.3b37.2x37.6x5.4x
Sat, 26 Nov 2022CHF 54.9bCHF 9.2bCHF 1.3b41.1x41.3x6x
Mon, 24 Oct 2022CHF 51.5bCHF 9.2bCHF 1.3b40.2x38.7x5.6x
Wed, 21 Sep 2022CHF 48.8bCHF 9.2bCHF 1.3b38x37.7x5.3x
Fri, 19 Aug 2022CHF 58.9bCHF 9.0bCHF 1.3b45x45.5x6.5x
Sun, 17 Jul 2022CHF 56.3bCHF 8.5bCHF 1.1b34.1x52.2x6.6x
Tue, 14 Jun 2022CHF 53.8bCHF 8.5bCHF 1.1b45.5x49.8x6.3x
Thu, 12 May 2022CHF 54.2bCHF 8.5bCHF 1.1b42.5x50.2x6.4x
Sat, 09 Apr 2022CHF 70.2bCHF 8.3bCHF 1.1b56.9x65.1x8.5x
Mon, 07 Mar 2022CHF 65.2bCHF 8.1bCHF 1.1b53.1x59.7x8x
Wed, 02 Feb 2022CHF 69.3bCHF 8.0bCHF 1.1b67.3x65.8x8.7x
Fri, 31 Dec 2021CHF 84.4bCHF 7.4bCHF 929.0m96.9x90.9x11.4x
Sun, 28 Nov 2021CHF 79.7bCHF 7.4bCHF 918.3m83.2x86.8x10.8x
Price to Earnings Ratio

86.8x


Total Market Cap: CHF 79.7bTotal Earnings: CHF 918.3mTotal Revenue: CHF 7.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Clinical Research and Equipment Industry Price to Earnings3Y Average 47.3x202220232024
Current Industry PE
  • Investors are optimistic on the Swiss Life Sciences Tools and Services industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 54.9x which is higher than its 3-year average PE of 47.3x.
  • The 3-year average PS ratio of 6.1x is higher than the industry's current PS ratio of 5.1x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 12% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Comparison

How does Swiss Clinical Research and Equipment compare with similar industries?

CH Market-1.36%
Healthcare-3.40%
Life Sciences-6.94%
Clinical Research and Equipment-6.94%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
No data available
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseWhat's New
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

TECN

CHF 210.00

Tecan Group

7D

-1.8%

1Y

-32.0%

SKAN

CHF 73.20

SKAN Group

7D

-7.1%

1Y

-9.1%

XLS

CHF 26.70

Xlife Sciences

7D

-5.3%

1Y

-32.4%

PPGN

CHF 27.00

PolyPeptide Group

7D

-12.1%

1Y

36.2%

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price

Nov 11
PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price

BANB

CHF 67.80

Bachem Holding

7D

-8.9%

1Y

-4.1%

Here's Why We Think Bachem Holding (VTX:BANB) Is Well Worth Watching

Nov 10
Here's Why We Think Bachem Holding (VTX:BANB) Is Well Worth Watching

SFZN

CHF 1,100.00

Siegfried Holding

7D

-3.2%

1Y

39.5%

Siegfried Holding AG's (VTX:SFZN) Price In Tune With Earnings

Nov 09
Siegfried Holding AG's (VTX:SFZN) Price In Tune With Earnings

LONN

CHF 517.00

Lonza Group

7D

-7.3%

1Y

46.8%

Is Lonza Group (VTX:LONN) Using Too Much Debt?

Nov 08
Is Lonza Group (VTX:LONN) Using Too Much Debt?